Humira (Adalimumab)

Humira is a prescription medication whose active ingredient is adalimumab, supplied as a sterile solution for subcutaneous injection. While specific strength varies by market, the product is formulated for single‑use or multi‑dose pens and is regulated in the European Union. It belongs to the TNF inhibitor class and is used to modify immune system activity in several inflammatory conditions.

Humira is indicated for a range of autoimmune and inflammatory disorders where tumor necrosis factor‑alpha (TNF‑α) plays a key role. It is prescribed by healthcare professionals based on individual disease severity and response.

- Rheumatoid arthritis in adults and children - Psoriatic arthritis and plaque psoriasis - Ankylosing spondylitis - Crohn's disease and ulcerative colitis - Hidradenitis suppurativa - Juvenile idiopathic arthritis and non‑infectious uveitis

Adalimumab may cause a variety of adverse reactions, ranging from mild to severe. Patients should be monitored for any new symptoms during therapy.

Common: - Injection site pain, redness, or swelling - Upper respiratory tract infections - Headache - Nausea - Mild rash or itching

Serious: - Serious infections such as tuberculosis, bacterial sepsis, or fungal infections - Reactivation of hepatitis B virus - Malignancies including lymphoma and skin cancers - Neurological events like demyelinating disease - Severe allergic reactions (anaphylaxis, serum sickness)

Before starting Humira, clinicians assess several health factors to minimize risk. Patients should be informed about necessary monitoring and lifestyle considerations.

- Screen for latent tuberculosis and hepatitis B prior to initiation - Evaluate for active infections; avoid use during uncontrolled infections - Caution in patients with a history of malignancy or demyelinating disorders - Monitor for signs of heart failure or worsening cardiac symptoms - Discuss vaccination status; avoid live vaccines during treatment - Use pregnancy and breastfeeding only if benefits outweigh potential risks

Humira can influence the activity of other medicines, and some combinations may increase infection risk or alter immune response.

Avoid: - Live attenuated vaccines (e.g., measles, varicella) due to reduced vaccine efficacy - Concurrent use with other biologic immunosuppressants unless specifically directed

Use with caution: - Systemic corticosteroids, which may heighten infection risk - Conventional disease‑modifying antirheumatic drugs (DMARDs) such as methotrexate - Antiviral agents for hepatitis B, requiring close monitoring - Immunizations with inactivated vaccines, which remain safe but may have reduced response